# US 12,268,719 B2 · Bacteriophage composition and method of preventing bacterial infections in livestock

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,268,719 B2
- Document ID: US12268719B2
- Status: Granted
- Kind: B2
- Application number: 18/493,396
- Filed: 2023-10-24
- Published: 2024-03-14
- Granted: 2025-04-08
- Earliest claimed: 2017-09-15
- Assignees: Syntbiolab Inc.
- Applicants: Syntbiolab Inc.
- Inventors: Rodrigue Dubar; Simon Labrie
- Web page: https://patentgrep.com/patent/US12268719B2

## CPC

- A23K 10/16: Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A23K 10/18: of live microorganisms
- A23K 50/30: for swines
- A23K 50/75: for poultry
- A61P 31/04: Antibacterial agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/00051: Methods of production or purification of viral material
- Y02A 40/70: in livestock or poultry
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides new bacteriophages, their selection, compositions, cocktails and formulations thereof, and their administration for the prevention of opportunistic infections in livestock, such as Avian Pathogenic E. Coli (APEC) infections in poultry.

## Claims

### Claim 1

A method for evaluating cross-resistance of at least two bacteriophage strains being screened for inclusion in a bacteriophage cocktail against a pathogenic bacteria, the method comprising:
providing a first and a second bacteriophage strain that infect the pathogenic bacteria, the second bacteriophage strain being different from the first bacteriophage strain;
culturing the first bacteriophage strain in the presence of said pathogenic bacteria at a Multiplicity of Infection (MOI) of at least about 1 until said bacteria develop resistance to the first bacteriophage strain, thereby producing a Bacteriophage Insensitive Mutant (BIM) pathogenic bacterial strain;
challenging the BIM pathogenic bacterial strain with the second bacteriophage strain; and
determining the absence of cross-resistance when the second bacteriophage strain still inhibits the growth of the BIM pathogenic bacterial strain.

### Claim 2 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on an absence of a gene encoding an integrase.

### Claim 3 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on an absence of a 16s rRNA gene marker.

### Claim 4 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on an absence of a gene encoding a human toxin.

### Claim 5 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on an absence of an antibiotic resistance gene.

### Claim 6 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on a burst size greater than 10 against said pathogenic bacteria.

### Claim 7 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on their stability at acidic pH.

### Claim 8 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on their stability at a temperature between 4° C. and room temperature (RT).

### Claim 9 (depends on 1)

The method of claim 1, further comprising characterizing the at least two bacteriophage strains based on:
(i) an absence of a gene encoding an integrase;
(ii) an absence of a 16s rRNA gene marker;
(iii) an absence of a gene encoding a human toxin;
(iv) an absence of an antibiotic resistance gene;
(v) a burst size greater than 10 against said pathogenic bacteria;
(vi) stability at acidic pH;
(vii) stability at a temperature between 4° C. and room temperature (RT); or
(viii) any combination of (i) to (vii).

### Claim 10 (depends on 1)

The method of claim 1, wherein the pathogenic bacteria are: Salmonella enterica, Listeria monocytogenes, Escherichia coli, Campylobacter jejuni, Staphylococcus aureus, or Clostridium perfringens.

### Claim 11 (depends on 1)

The method of claim 1, wherein the bacteriophage cocktail comprises at least three bacteriophage strains.

### Claim 12 (depends on 1)

The method of claim 1, wherein the bacteriophage cocktail comprises at least four bacteriophage strains.

### Claim 13 (depends on 1)

The method of claim 1, wherein the bacteriophage cocktail comprises at least five bacteriophage strains.

### Claim 14 (depends on 1)

The method of claim 1, wherein the at least two bacteriophage strains are further characterized in that they have different host ranges against at least two different pathogenic bacteria causing opportunistic bacterial infections in livestock.

### Claim 15 (depends on 1)

The method of claim 1, wherein the at least two bacteriophage strains are further characterized in that they have complementary host ranges against at least two different pathogenic bacteria causing infections in livestock.

### Claim 16 (depends on 1)

The method of claim 1, wherein the pathogenic bacteria are extra-intestinal pathogenic Escherichia coli (ExPEC) or avian Pathogenic E. coli (APEC).

### Claim 17 (depends on 1)

The method of claim 1, wherein the at least two bacteriophage strains comprise a sequence selected from the group consisting of: SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28.

### Claim 18 (depends on 1)

The method of claim 1, wherein the at least two bacteriophage strains are selected from those defined by the deposits filed at the International Canadian Depository Authority (IDAC) on Sep. 7, 2018 and bearing numbers #: 070918-02; 070918-03; 070918-04; 070918-05; and 070918-06.

### Claim 19 (depends on 1)

The method of claim 1, wherein the at least two bacteriophage strains have complementary host ranges against at least two different bacterial strains selected from the group consisting of: Avian Pathogenic Escherichia coli (APEC)-A, APEC-B, APEC-C, APEC-D, APEC-E, and APEC-F.

### Claim 20 (depends on 15)

The method of claim 15, wherein the livestock is poultry or pigs.
